Kudos to Aultman Health Foundation for enrolling their first patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. bit.ly/pre1702-study

Great work to Montefiore for enrolling their first patient in PrE0510! This #ClinicalTrial is a phase II study of platinum/​etoposide plus ivonescimab for extensive-stage small cell lung cancer (#SCLC). Learn more here: bit.ly/PrE0510

Kudos to Aspirus Regional Cancer Care for enrolling their first patient in PrE0510! This #ClinicalTrial is a phase II study of platinum/​etoposide plus ivonescimab for extensive-stage small cell lung cancer (#SCLC). Learn more here: bit.ly/PrE0510

Great work to FirstHealth of the Carolinas-Moore Regional Hospital for enrolling their first patient in #RealWorldData #PatientRegistry PrE1702! Learn more: bit.ly/pre1702-study

Kudos to @carlehealth.bsky.social for enrolling their first patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. bit.ly/pre1702-study

FirstHealth of the Carolinas-Moore Regional Hospital
is enrolling patients in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. More: bit.ly/pre1702-study

Great work to @choosesjc.bsky.social for enrolling their first patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. bit.ly/pre1702-study

Kudos to Tufts Medical Center for enrolling their first patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. bit.ly/pre1702-study

@choosesjc.bsky.social is now enrolling patients in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. Learn more: bit.ly/pre1702-study

Primary Analysis and Results of Bendamustine, Rituximab, and Venetoclax (BR-VEN) for Initial Treatment of Mantle Cell Lymphoma in Subjects over 60 Years of Age (PrE0405) BackgroundMantle cell lymphoma (MCL) is an incurable form of aggressive non-Hodgkin lymphoma. Treatment choice at diagnosis is based on tolerability o…

#FindingsFriday: ICYMI, new data from @precogonc.bsky.social PrE0405, presented at #ASH25, showed that treatment with BR-VEN led to high response rates & promising CR rates for older patients w/ mantle cell #lymphoma. More: bit.ly/4aReE69 #MCL

UM Greenebaum Comprehensive Cancer Center is now enrolling patients in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. Learn more: bit.ly/pre1702-study

Great work to ThedaCare for enrolling their first patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. bit.ly/pre1702-study

Kudos to Montefiore Medical Center for enrolling their first patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. bit.ly/pre1702-study

New @nejm.org | PATINA ph 3 trial | Adding #Palbociclib significantly improves progression-free survival in patients w/ HR+ HER2+ metastatic #BreastCancer | Prolonged disease control for an incurable condition | bit.ly/PATINAresults

Aspirus Cancer Center Wausua is now enrolling patients in PrE0510! This #ClinicalTrial is a phase II study of platinum/​etoposide plus ivonescimab for extensive-stage small cell lung cancer (#SCLC). Learn more here: clinicaltrials.gov/study/NCT070...

Federal Funding for Cancer Research As Congress negotiates Fiscal Year 2025 appropriations bills, urge them to make cancer research a top priority.

DYK funding for NIH and NCI ends on 1/30? Act now & ask Congress to support sustainable, long-term funding for biomedical & #CancerResearch for FY26: bit.ly/3LpZJau

Kudos to Stanford Cancer Institute Palo Alto for enrolling their first patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. bit.ly/pre1702-study

Great work to Baptist Memorial Health Care for enrolling their first patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. bit.ly/pre1702-study

Tufts Medical Center is now enrolling patients in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. Learn more: bit.ly/pre1702-study

Guide to ASH 2025: ECOG-ACRIN and PrECOG are set to reveal multiple blood cancer research discoveries Lear more about the 11 in-depth scientific analyses aim to enhance the precision and safety of treatments for hematologic malignancies.

At #ASH2025, ECOG-ACRIN & @precogonc.bsky.social researchers will present data that could improve treatments for #AML, #ALL, #MCL, #CLL and more. View our full guide to the meeting: bit.ly/4rtkbHp #BloodCancer #leukemia #lymphoma

Geisinger Cancer Institute is now enrolling patients in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. Learn more: bit.ly/pre1702-study

Great work to Vanderbilt University Medical Center for enrolling their first patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. bit.ly/pre1702-study

@stanford-cancer.bsky.social is now enrolling patients in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. Learn more: bit.ly/pre1702-study

In honor of #LungCancer Awareness Month, learn about PrE0510! This #ClinicalTrial is a phase II study of platinum/​etoposide plus ivonescimab for extensive-stage small cell lung cancer (#SCLC). Click here for more 👉 bit.ly/49xgUR3 #LCAM #LCSM

Ongoing Trials: A closer look at ECOG-ACRIN’s clinical trials for patients with pancreatic conditions For Pancreatic Cancer Awareness Month, we highlight two actively recruiting clinical trials for patients with pancreatic conditions

On #WorldPancreaticCancerDay 💜 we are shining a light on two @eaonc.bsky.social clinical trials aiming to improve outcomes for patients with #PancreaticCancer & #PancreaticCysts - EA2185 and EA2192/APOLLO. Learn more here 👉 bit.ly/pancreaticf25

Kudos to @virtuahealth.bsky.social for enrolling their first patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. Learn more: bit.ly/pre1702-study

Durvalumab Plus Chemo Yields Inconclusive Results in Advanced Pleural Mesothelioma | OncLive Durvalumab in combination with chemotherapy produced outcomes consistent with prior studies in patients with advanced pleural mesothelioma.

The recently reported DREAM3R results show that, for pts w/ pleural #mesothelioma, the addition of durvalumab to chemo = higher tumor response—yet survival benefit is unclear. More research is needed. Read about this collab between @precogonc.bsky.social & @togaanz.bsky.social: bit.ly/47Pw02S

Spotlight on Real-World Data Capture: The PrE1702 Registry Study in Lung Cancer This major new initiative is a unique opportunity for researchers and patients to help build an important real-world data registry of patients with EGFR-mutated non-small cell lung cancer

Great work to ProHealth Care for enrolling their first patient in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. More: bit.ly/4hyZUue #LCSM

Thomas Jefferson University Hospital is now enrolling patients in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. Learn more: bit.ly/pre1702-study

Spotlight on Real-World Data Capture: The PrE1702 Registry Study in Lung Cancer This major new initiative is a unique opportunity for researchers and patients to help build an important real-world data registry of patients with EGFR-mutated non-small cell lung cancer

Marshfield Clinic is now enrolling patients in #RealWorldData #PatientRegistry PrE1702! This study is evaluating how well osimertinib +/- chemo/IO works to control EGFR+ #LungCancer in patients not in a #ClinicalTrial. bit.ly/4hyZUue